D espite extensive investigations, the cellular and molecular mechanisms that contribute to myocardial ischemia are not well understood, and to date, no infarct sparing therapeutic interventions, other than early perfusion, have been developed. Previous studies show that during ischemia, inhibition of the mitochondrial respiratory chain perturbs electron transport, leading to an increase in the generation of free radicals.
D
injury is caused by other secondary species generated by the free radicals.
Free radicals generated during I/R are short lived, and their ability to induce tissue injury is paradoxically limited by their high reactivity. Because these radicals react readily with neighboring molecules, most are unable to diffuse away from their site of formation and cause only site-specific damage. It is, therefore, likely that tissue injury attributed to free radicals is caused by secondary, more-stable species that the radicals generate. Although free radicals generate a range of secondary species, products of lipid peroxidation have received the most attention. 5 Membrane lipids are the most vulnerable targets of free radicals, and even transient increases in free radicals are associated with the accumulation of lipid peroxidation products. Therefore, increased production and accumulation of lipid oxidation products could account for much of the tissue injury attributed to free radicals.
Of the several products generated by oxidized lipids, unsaturated aldehydes are some of the most toxic species. 6 These aldehydes are generated in high abundance, and they avidly react with tissue nucleophiles leading to depletion of reduced glutathione (GSH) and covalent modification of nucleophilic protein side chains and nucleotides. Moreover, unlike their radical progenitors, aldehydes can diffuse away from their site of origin and thereby prolong and amplify oxidative injury. However, tissue reactivity of aldehydes is regulated by processes involved in their metabolism and detoxification. 7 In most tissues, aldehydes are either reduced or oxidized to less reactive products. In addition, unsaturated aldehydes are conjugated to GSH and are excreted as mercapturic acids in the urine. Although unsaturated aldehydes spontaneously react with GSH, this reaction is further accelerated by glutathione S-transferases (GSTs), which augments detoxification and decreases tissue accumulation of unsaturated aldehydes.
The GSTs represent a family of phase II enzymes that are expressed to high abundance in most tissues. At least 16 genes encode GSTs in the cytosol, and 6 GST gene products are localized in the membrane. 8 These proteins catalyze glutathione conjugation with a range of endogenous and xenobiotic substrates. 9 Several GSTs are involved in the metabolism and detoxification of unsaturated aldehydes: GST4-4 catalyzes the addition of glutathione to aldehydes, such as 4-hydroxy-trans-2-nonenal (HNE), 10 whereas GSTP supports glutathiolation of small chain aldehydes, including acrolein and base propenals. 11 GSTP is the major extrahepatic GST isoform. Previous studies have shown that fibroblasts isolated from GSTP-null mice are more sensitive to various forms of oxidative stress, including UV radiation and H 2 O 2 , and that deletion of GSTP increases tumor formation and growth. 12 Nevertheless, the role of GSTP in myocardial ischemic injury has not been studied.
This study was designed to test the hypothesis that myocardial ischemic injury is mediated, in part, by unsaturated aldehydes, and thus, the detoxification of these aldehydes by GSTP protects the heart from oxidative damage during I/R. The results of this study show that genetic deficiency of GSTP diminishes aldehyde detoxification in the heart and exacerbates myocardial I/R injury. These findings reveal a new mechanism of cardioprotection and support the notion that aldehydes generated in the ischemic heart are a significant cause of tissue injury and cell death.
Methods
Detailed methodology is provided in the Online Data Supplement. Wild-type (WT) and GSTP-null mice, generated on an MF1 background strain using homologous recombination, 12 were bred for >12 generations with C57BL/6J mice. The mice were treated in accordance with the Declaration of Helsinki and with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the US National Institutes of Health. All treatment protocols were approved by the Institutional Animal Care and Use Committee at the University of Louisville. The mice were genotyped using primers that amplified the region between exons 5 and 6 of GSTP1 and a region in the lacZ gene to identify a null allele. The mice were healthy and reproduced in a Mendelian fashion. Their cardiac function was measured by echocardiography after Avertin anesthesia at 12 to 16 weeks of age. In a subset of mice, LV mechanical function was assessed using a Millar pressure-conductance catheter as described previously. 13 
Cardiac Myocyte Isolation, Electrophysiology, and Hypercontracture

Isolation
Calcium-tolerant cardiomyocytes were isolated from the left ventricle using collagenase digestion as described previously.
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Electrophysiology
Whole-cell sodium currents were recorded by the patch-clamp technique at room temperature (21°C-22°C) as described before. 15, 16 The recording pipettes were filled with internal solution containing (in mmol/L) CsCl, 134; NaCl, 10; MgCl 2 , 1; Na 2 -ATP, 1; HEPES, 10; and EGTA, 10, adjusted to pH 7.2 with CsOH. Cells were superfused at 1 to 1.5 mL/min with bath solution containing (in mmol/L) NaCl, 20; CsCl, 129; CaCl 2, 1.8; MgCl 2 , 1; HEPES, 10; and LaCl 3 0.5, adjusted to pH 7.4 using CsOH. Cs 2+ and La 3+ were used to block K + -and Ca
2+
-dependent currents, respectively.
Hypercontracture
After isolation, myocytes were incubated overnight in laminin-coated plates, and then to measure oxidant sensitivity, myocytes were superfused in an oxygenated-HEPES buffer without or with acrolein or H 2 O 2 for 60 minutes. As indicated, in some experiments, the cells were preincubated with an NCX1 inhibitor 17 SN-6 (10 μmol/L; 30 minutes) before superfusion with acrolein (25 μmol/L) for 60 minutes in HBSS. Digital images of myocytes (60-100 per field) were used for quantification of the total number of rod-shaped cells as previously described. 14, 18 
I/R Injury
Mouse hearts were subjected to I/R ex vivo in the Langendorff mode or to coronary occulsion and reperfusion in situ. These models have been described in detail before. 19, 20 For ex vivo perfusion, the hearts were perfused at a constant pressure (≈80 mm Hg) with Krebs-Henseleit buffer containing (in mmol/L) NaCl, 118; KCl, 4. 
Electron Paramagnetic Resonance Spectroscopy
Free radical generation was measured in isolated perfused hearts. After ischemia, the spin trap 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) in buffer containing 100 µmol/L diethylenetriaminepentaacetic acid was infused in the heart at a rate of 100 µL/min through a side arm located close to the heart. The effluent was collected at indicated times after reperfusion, and each tube was frozen immediately in liquid nitrogen. Electron paramagnetic resonance spectra were recorded and analyzed as previously described.
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Acrolein Measurement
For measuring free acrolein in perfused hearts subjected to ischemia, we used a carbonyl derivatizing reagent, N- [2-(aminooxy) ethyl]-N,Ndimethyl-1-dodecylammonium iodide (QDA; 13 CD 3 -QDA internal standard), 22 and ultra-performance liquid chromatography-mass spectrometry multiple reaction monitoring with femtomole sensitivity.
Aldehyde Metabolism
For measuring acrolein and HNE metabolism, cardiac lysates (2 mg/ mL) were incubated with GSH (100 µmol/L) and indicated concentrations of either acrolein or HNE. The GS conjugate formed in the reaction mixture was separated by high-performance liquid chromatography and quantified by electrospray ionization-mass spectrometry using either GS- 13 C-propanal or GS- 13 C-4HNE as internal standards.
Protein Expression, Abundance, and Enzyme Activity
Western blots were developed using commercially available antibodies against GSTA, M, and P. Western blots were scanned on a Typhoon 9600, and band density of interest was normalized to α-tubulin staining band density. Total GST conjugating activity toward substrates 1-chloro-2,4-dinitrobenzene (1 mmol/L) and ethacrynic acid (200 µmol/L) was measured in cardiac homogenates as reported previously.
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Histology and Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections (4 µm) were stained with hematoxylin and eosin, anti-GSTP1 antibody (1:1500; Novocastra), 25 IgG-purified polyclonal rabbit antiprotein-acrolein antibody (1:1000), 23 or murine antimyeloperoxidase antibody (Ab-1; Thermo Fisher Scientific). 23 Images of midheart cross sections were made using a digital Spot camera mounted on an Olympus microscope and analyzed using Metamorph (Molecular Devices).
Statistical Analysis
Data are presented as mean±SEM. For different treatment groups, data were compared using paired or unpaired t test or 1-way ANOVA with repeated measures and Dunnett or Bonferroni post-test where appropriate (SigmaStat, SPSS, Inc, Chicago, IL). Mean lifetime (µ, minutes) of cardiac myocytes superfused with oxidants was calculated using the Weibull distribution as described before.
14 P<0.05 was considered statistically significant.
Results
Cardiac Distribution of GSTP1/P2 Protein
Most tissues express several GST isoforms. To determine the expression of GST isoforms in the heart, we measured the relative expression of the 3 major GST isoforms-GS-TA (α), GSTM (μ), and GST P1/P2 (π) in the hearts of WT and GSTP-null mice. Real-time polymerase chain reaction analysis showed that mGstp1/2 was the most abundant GST transcript followed by mGsta4 and mGstm4.1 ( Figure 1A ). Real-time polymerase chain reaction and Western blotting did not show a compensatory increase in the expression of GSTA and GSTM isoforms in GSTP-null mice ( Figure 1A and 1B) . Immunohistochemical studies showed diffuse localization of GSTP in the myocardium with positive immunoreactivity associated with cardiac myocytes and coronary blood vessels. No positive immunohistochemical reactivity was observed in GSTP-null hearts ( Figure 1C ). Subcellular fractionation showed that GSTP was localized mainly in the cytosolic (>50%) and the nuclear fractions, although low levels of the protein were also detected in the microsomal and mitochondrial fractions ( Figure 1D ). GST activity measured with 1-chloro-2,4-dinitrobenzene, which is conjugated by most GSTs, as well as ethacrynic acid, a GSTP-specific substrate, was significantly lower in subcellular fractions of GSTP-null hearts compared with WT hearts (Figures 1E and 1F) indicating that GSTP contributes significantly to total GST conjugating activity in the heart. There were no differences, however, in protein abundance (Online Figure IA) or the activity (Online Table  II ) of major antioxidant enzymes, including superoxide dismutase (SOD), glutathione reductase, glutathione peroxidase, aldose reductase, and thioredoxin between WT and GSTP-null hearts. A small (8%), but statistically significant, difference in catalase activity was observed, but this is unlikely to be physiologically significant. Similarly, the inducible proteins, inducible nitric oxide synthase and heme oxygenase-1, were not detected in WT or GSTP-null hearts (Online Figure IB) , and there was no difference in the basal level of protein-HNE adducts (Online Figure IC) . Collectively, these data indicate that GSTP is a major cardiac GST isoform and that GSTP deficiency does not result in compensatory changes in other GSTs or in persistent oxidative stress.
Cardiac Function
Cardiac dimensions and function in GSTP-null mice were similar to aged-matched WT mice (Online Table III) . No significant differences between LV or heart/body weight ratios or heart rate were observed. Although both LV end-diastolic volume and ejection fraction were slightly higher in GSTPnull mice, these differences were slight, indicating that genetic deficiency of GSTP does not markedly alter cardiac dimension or function.
GSTP and I/R Injury
To determine whether GSTP prevents ischemic injury, WT and GSTP-null mice were subjected to 30 minutes of coronary occlusion followed by 4 hours of reperfusion. In WT mice, this procedure resulted in the large infarcts that were on average 55.6±3.9% of the area-at-risk. In comparison, the GSTPnull mice were more sensitive to ischemia; the infarct size in these mice was 73.1±3.7% of the area-at-risk (Figure 2Ai and 2Aiii). These observations suggest that genetic deficiency of GSTP results in greater myocardial injury induced by coronary ligation. Because GSTP deletion could affect a variety of systemic responses that could indirectly affect myocardial ischemic injury, we examined whether hearts isolated from GSTP-null mice were more sensitive to I/R injury. In isolated perfused WT hearts, global ischemia for 30 minutes significantly suppressed contractile function, and after 45 minutes of reperfusion, the recovery of developed pressure was ≈30% of its preischemic value ( Figure 2B ; Online Figure II) . In contrast, in GSTP-null hearts, there was <15% recovery in developed pressure, indicating that GSTP deficiency decreases post ischemic recovery ( Figure 2B ). In addition, the release of the myocardial enzymes, lactate dehydrogenase and creatine kinase, which is indicative of cell death, was significantly higher in GSTP-null than WT hearts (Figure 2Ci and 2Cii) . No significant difference in heart rate (at baseline or after reperfusion) was observed between WT and GSTP-null hearts. These data indicate that deletion of GSTP increases myocardial sensitivity of I/R injury, independent of any systemic factors, and that in both in situ and ex vivo models, the absence of GSTP exacerbates I/R injury.
Cardioprotective Mechanism of GSTP
Because GSTP is a multifunctional protein, we considered several mechanisms by which it could affect I/R injury. These are described below.
Regulation of GSH Levels
GSTP catalyzes the conjugation of glutathione with electrophilic substrates; therefore, the absence of the enzyme could increase tissue glutathione levels. However, our measurements showed that there was no difference in the levels of GSH between perfused WT (GSH, 2.56±0.26 nmol/mg, wet weight; n=7) and null (GSH, 3.27±0.42 nmol/mg, wet weight; n=7) hearts. After 15 minutes of ischemia and 15 minutes of reperfusion, levels of reduced GSH were decreased by ≈20% in both WT and GSTP-null mice when compared with hearts subjected to perfusion alone ( Figure 3A) . These results indicate that GSTP deficiency does not exacerbate ischemic depletion of GSH in the heart, and therefore, the effects of GSTP on myocardial I/R injury are unlikely to be mediated by changes in GSH levels.
c-Jun N-Terminal Kinase Activation
Previous studies have shown that genomic deletion of mGstp1/p2 leads to constitutive activation of c-Jun N-terminal kinase (JNK) in the liver and the lung. 26 Hence, GSTP could affect JNK activity, which in turn could alter myocardial sensitivity to I/R injury. However, we found that the basal levels of phospho-JNK and JNK activity (measured as phosphorylated c-jun) were similar between WT and GSTP-null hearts, suggesting that in the heart, unlike the lung or the liver, 26 the levels of constitutively active JNK are not elevated by GSTP deletion. Moreover, coronary occlusion for 15 minutes, followed by 15 minutes of reperfusion, significantly increased phospho-JNK levels in both WT and GSTP-null hearts in the area-at-risk but not in the nonischemic zone (posterior wall LV; Figure 3Bi and 3Biii) . The level of phospho-JNK in the ischemic zone was not different in GSTP-null hearts compared with WT hearts, indicating that the absence of GSTP did not enhance JNK activation during I/R. Moreover, the levels of phosphorylated c-Jun were not different in the ischemic zone of WT and GSTP-null hearts (Figure 3Bii and 3Biii ). These observations suggest that GSTP-mediated cardioprotection is unlikely to be related to changes in JNK activation.
Oxidative Stress
To examine whether GSTP regulates the production of free radicals on reperfusion, we measured free radicals in the perfusates of perfused heart and lipid peroxidation-derived aldehyde in cardiac lysates. To measure free radicals, hearts were perfused with the radical trap DMPO and stable radical-DMPO adducts in the perfusate were measured by electron paramagnetic resonance. 20 Under these conditions, peak radical signal was detected within 1 minute of reperfusion, and the electron paramagnetic resonance signal diminished over the next 4 minutes to baseline in both WT and GSTP-null hearts ( Figure 4A ). There was no difference in peak signal intensity and reactive oxygen species area under the curve ( Figure 4B ) between WT and GSTP-null hearts. In addition, the abundance of DMPO-modified proteins was similar in WT and GSTP-null hearts ( Figure 4C ), suggesting that disruption of GSTP does not increase the formation of proteinradicals in the hearts. Collectively, these observations indicate that both WT and GSTP-null hearts generate equal levels of reactive oxygen species and that deletion of GSTP does not increase free radical production in hearts subjected to I/R. To determine whether GSTP deficiency affects the basal levels and ischemia-induced increase in lipid peroxidation-derived aldehydes, we measured myocardial levels of free malondialdehyde, hexanal, or HNE in perfused hearts and in hearts subjected to I/R by gas chromatography/mass spectrometry. We found no difference in the levels of these aldehydes in WT and GSTP-null hearts (Online Table IV ), indicating that GSTP activity does not regulate malondialdehyde, hexanal, or HNE levels. Similarly, the ischemia reduced glutathione/ oxidized glutathione ratio was not different between WT and GSTP-null hearts (Online Table V ). Collectively, these results suggest that GSTP deficiency does not increase generalized oxidative stress in the heart during I/R.
Acrolein Formation, Metabolism, and Toxicity
A previous study showed that both left ventricular pacing and heart failure generate lipid peroxidation products including unsaturated aldehydes, such as HNE; however, free acrolein has not been detected in the ischemic heart. 27 Hence, we measured free acrolein using an ultra-performance liquid chromatography-mass spectrometry and multiple reaction monitoring method in perfused hearts subjected to global ischemia for 15 minutes with QDA that binds acrolein. The native acrolein-QDA adduct recovered from ischemic hearts had an elution and ion fragmentation profile identical to an isotopic internal standard 13 CD 3 -QDA-acrolein ( Figure 5A and 5B). These measurements showed that in comparison with hearts perfused under aerobic conditions, hearts subjected to ischemia had significantly higher levels of free acrolein ( Figure 5C ), indicating that myocardial ischemia results in acrolein formation.
Previous work has shown that GSTP catalyzes the glutathione conjugation of short-chain aldehydes, such as acrolein. Therefore, GSTP deficiency could increase I/R injury by preventing the metabolism and detoxification of aldehydes, such as acrolein generated in the ischemic heart. Acrolein is a reactive and toxic aldehyde that is generated during peroxidation of membrane lipids 28 and as a product of myeloperoxidase-catalyzed reactions. 29 Hence, we tested whether GSTP catalyzes the conjugation of acrolein in the heart and whether acrolein accumulation could account for the greater I/R injury in GSTPnull hearts. We found that incubation of acrolein with GSH led to the spontaneous formation of the glutathione-acrolein conjugate (oxopropyl glutathione), which could be detected by mass spectrometry using reagent 13 C-oxopropyl glutathione as an internal standard ( Figure 5D ). The extent of formation of the glutathione conjugate was significantly increased when acrolein and GSH were coincubated with cardiac lysates from WT mice, indicating that the reaction is catalyzed by cardiac GSTs. Moreover, the extent of oxopropyl glutathione formation was consistently lower in GSTP-null than in WT hearts (−33±13% of WT activity; Figure 5E ). Under similar experimental conditions, there was no significant difference in GS-HNE formation between GSTP-null and WT hearts (−17±13% of WT activity; n=3). Taken together, these data indicate that genetic deletion of GSTP decreases the rate of conjugation of acrolein with glutathione, whereas the formation of the glutathione conjugation of HNE is not affected. Therefore, the deficiency of GSTP could diminish acrolein metabolism and thereby increase the toxicity of acrolein generated during I/R.
To determine whether GSTP deficiency affects the fates of acrolein generated in the heart, we measured changes in the formation of protein-acrolein adducts in WT and GSTPnull hearts subjected to I/R. The formation of protein-acrolein adducts was used as an indirect index of acrolein fate in the heart because acrolein is highly reactive, and therefore, the levels of free acrolein are likely only a fraction of what reacts with nucleophilic cell constituents. Immunohistochemical analysis showed extensive positive reactivity with polyclonal acrolein-protein antibodies in the peri-infarct region of hearts subjected to coronary ligation in situ (Figure 6Ai ). Significantly, a near absence of antiprotein-acrolein staining was observed within the infarct zone, indicating that the increased protein modification by acrolein is not because of cell death and that these adducts are not associated with the dead tissue within the infarct. Indeed, what little staining that was present in the infarct zone ( Figure 6Aii ) was colocalized with inflammatory cells stained for myeloperoxidase protein (Figure 6Aiii ). Similarly, in isolated perfused hearts, we found that 15 minutes of ischemia led to a significant increase in the formation of protein-acrolein adducts in WT hearts ( Figure 6B, I ), which generally decreased on reperfusion ( Figure 6B , R). Moreover, under each experimental condition, the intensity of staining seemed higher in GSTP-null than in WT hearts ( Figure 6B, I ). To quantify total proteinacrolein adducts generated in the heart, slot blots were developed using lysates of WT and GSTP-null hearts subjected to 15 minutes of ischemia. As shown in Figure 6C , there was an increase in protein-acrolein adduct formation in WT hearts on ischemia. The basal abundance of protein-acrolein adducts in perfused GSTP-null hearts was similar to that in WT hearts; after ischemia, there was an increase in adduct formation, which was significantly more in GSTP-null than WT hearts. The results of Western blot analysis revealed that the intensity of several protein bands (M r , ≈75, ≈70, and ≈27) was higher in GSTP-null than in WT hearts (Figure 6Di and 6Dii). Moreover, incubation of isolated cardiac myocytes with acrolein led to the modification of several proteins and prominent increase in reactivity with protein-acrolein antibody was observed with a protein band corresponding to 250 kDa, likely formed by cross-linked protein (Online Figure  IVA) . Removal of acrolein from the medium led to timedependent decrease in the intensity of this band in WT but not in GSTP-null cardiac myocytes, in which the intensity of the band continued to increase for the next 60 minutes (Online Figure IVB) . Taken together these results suggest that I/R increases the formation of acrolein-modified proteins and that GSTP deficiency results in a greater accumulation of protein-acrolein adducts in both ischemic and reperfused hearts. Some acrolein modified proteins could be detected also in isolated cardiac myocytes incubated with acrolein and that the formation and the persistence of these bands was higher in GSTP-null than in WT myocytes, is consistent with the key role of GSTP in preventing acrolein-induced protein modification.
Given our observations suggesting that GSTP deficiency increases the formation of protein-acrolein adducts, we tested the possibility that acrolein by itself could induce cardiac myocyte cell death and determined its underlying mechanism. Previous studies have shown that I Na is a critical target of reactive products generated by lipid peroxidation 18, 30 and that perturbations in I Na lead to an increase in [Na] i , which exchanges for extracellular calcium, via Na + -Ca 2+ exchange, leading to calcium overload, myocyte hypercontracture, and necrotic cell death. 14 To determine whether acrolein induces cell death via a similar mechanism, we examined acrolein-induced changes in I Na . Superfusion of isolated WT cardiac myocytes with acrolein led to a slight increase in the reversal potential of the current ( Figure 7A-7C) ; and a time-dependent shift in the 2) at 2.9 minutes is identical to *QDA-acrolein (m/z: 315.2). Inset: standard curve indicating limit of detection was in the subfemtomole range. C, Group data showing free acrolein in wild-type (WT) hearts perfused with aerobic buffer for 30 minutes or subjected to 15 minutes of ischemia (WT, n=7, 7; P=0.05). D, Representative electrospray ionization-mass spectrometry (ESI-MS) traces of oxopropyl glutathione formed (i) spontaneously or catalyzed in cardiac lysates prepared from either WT (ii) or GSTP-null hearts (iii). E, The percentage of oxopropyl glutathione (relative to WT) generated in cardiac homogenates from WT and GSTP-null hearts incubated with acrolein (10 µmol/L) and reduced glutathione (100 µmol/L) for 15 minutes. The concentration of oxopropyl glutathione generated in the lysates (m/z, 364) was quantified by ESI + -MS using 13 C-oxopropyl glutathione (m/z, 367) as an internal standard. *P<0.05 (n=6 per group).
by guest on November 18, 2017 http://circres.ahajournals.org/ Downloaded from voltage-dependence of activation toward more negative potentials (Figure 7Bi and 7Bii) and a corresponding increase in the window current ( Figure 7Ciii) ; effects not seen in myocytes superfused with Ringer's solution alone. To determine whether this was related to cell death, the myocytes were either left untreated or preincubated with SN-6 (an NCX1 inhibitor 17 ) and then superfused with acrolein. Superfusion with acrolein led to a time-dependent hypercontracture of myocytes in 57.3±2.9 minutes; however, in the presence of SN-6, the mean lifetime of acrolein-treated myocytes was significantly (P<0.01) increased to 70.7±4.7 minutes (Figure 7Di and 7Dii) , consistent with the notion that acrolein-induced hypercontracture is mediated by calcium-overload secondary to an increase in [Na] i via acrolein-induced changes in I Na . Finally, to determine whether GSTP levels affect acrolein-induced cell death, cardiac myocytes isolated from WT and GSTP-null hearts were superfused with acrolein. As before, superfusion with 10 μmol/L of acrolein-induced hypercontracture in most cells within 66.3±3.3 minutes (Figure 8A and 8B) . In comparison, myocytes isolated from GSTP-null hearts were more sensitive to acrolein (mean lifetime, 49.6±2.0 minutes; P<0.05 versus WT; Figure 8A and 8B). Similarly, GSTP-null myocytes were also more sensitive to hydrogen peroxide than myocytes isolated from WT hearts ( Figure 8C and 8D) . These results suggest that the absence of GSTP increases the sensitivity of these myocytes to peroxide-and acrolein-induced cell death and support the view that GSTP protects the heart from I/R injury by removing toxic lipid peroxidation products (Online Figure V) . 
Discussion
The results of this study show that GSTP is a cardioprotective protein that decreases the sensitivity of the heart to ischemic injury. Our results indicate that GSTP protects the heart by facilitating the metabolism and detoxification of small chain aldehydes, such as acrolein. Removal of these aldehydes by GSTP decreases tissue injury and prevents post-translational modification of myocardial proteins. The observation that genetic disruption of GSTP exacerbates myocardial injury without affecting free radical generation suggests that cardiac injury during ischemia and reperfusion is not because of free radicals themselves, but instead, it could be attributed to secondary oxidants, such as aldehydes. These findings uncover a novel mechanism of cardioprotection and add a new facet to our understanding of the role of oxidative stress in myocardial I/R injury.
Proteins of the GST family are phase II detoxification enzymes that catalyze the conjugation of glutathione with reactive metabolites or xenobiotics. These conjugative reactions neutralize toxic chemicals and facilitate their removal from the body. The GSTs have been widely studied for their role in imparting chemoresistance to tumor cells; however, their cardiovascular roles are less well understood. In several cell types, GSTs protect against oxidative injury by removing electrophilic oxidants. In particular, some GST isoforms, such as GSTA4-4 and GSTP1, catalyze the conjugation of glutathione with unsaturated aldehydes derived from lipid peroxidation; and therefore, it is currently believed that they are important antioxidant defense enzymes. We found that GSTP is the major isoform expressed in the heart, although we detected both GSTA and GSTM as well, which is similar to the pattern in human heart. 31, 32 Previous studies have shown that the human heart has less abundance of the major GST isoforms compared with the liver. 32 Consistent with its major role in xenobiotic detoxification, the liver possesses high GST activity, whereas heart GST activity is significantly less. 32 This difference suggests that in the heart, GSTs are involved in processes other than xenobiotic detoxification, although to date, their role remains unclear. Our observation that deletion of GSTP does not affect the development of the heart or its contractile function at baseline suggests that GSTP may not be an important regulator of normal cardiac development and physiology but that it might be required under conditions of injury or stress.
Given the extensive evidence supporting the antioxidant role of GSTs, we tested whether GSTP prevents oxidative injury induced by free radicals generated during I/R. We found that in both isolated perfused hearts and in hearts subjected to coronary ligation in situ, the absence of GSTP led to a consistent and robust increase in I/R injury. At baseline, deletion of GSTP did not induce a state of generalized oxidative stress, and there were no compensatory changes in glutathione levels, other GSTs, or antioxidant enzymes, suggesting that GSTP plays a unique, nonredundant role in protecting the heart from oxidants produced during ischemia and on reperfusion. Our results suggest that this protective role of GSTP relates to the detoxification of aldehydes, such as acrolein. Although GSTP is a multifunctional enzyme, it displays high catalytic efficiency with small aldehydes, such as acrolein and base propenals, but not other bulkier aldehydes, such as HNE.
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In agreement with this selectivity, we found that disruption of mGstp1/2 did not increase myocardial levels of HNE and hexanal, suggesting that changes in the levels of these aldehydes are unlikely to account for the cardioprotective effects of GSTP. Nevertheless, deletion of GSTP was accompanied by a significant decrease in the capacity of the heart to synthesize glutathione conjugates of acrolein and to prevent posttranslational modification of proteins by acrolein. In isolated cardiac myocytes, deletion of GSTP also increased the sensitivity to acrolein toxicity. Collectively, these observations support the view that the GSTP-null hearts are inefficient at metabolizing acrolein, and therefore, when generated during I/R, this aldehyde accumulates in the heart and contributes to tissue injury to a larger extent than in WT hearts.
Acrolein is a highly reactive, 3-carbon unsaturated aldehyde. It reacts readily with cellular nucleophiles, including GSH, histidine, lysine, and cysteine side chains of proteins, leading to the formation of covalent adducts that can modify protein function. Acrolein and acrolein-modified proteins have been detected in human atherosclerotic lesions 28 and in mouse hearts after myocardial infarction, where it has been suggested that acrolein is derived mainly from the oxidation of unsaturated lipids. 6, 33 Extensive accumulation of acroleinmodified proteins in the ischemic heart, observed in this study, is consistent with lipid peroxidation as the major source of acrolein in the heart. However, acrolein could also be generated by the catalytic oxidation of amino acids by myeloperoxidase or as a product of polyamine oxidase. 29, 34 Myeloperoxidase is highly expressed in neutrophils, and in infarcted mouse hearts, we found colocalization of myeloperoxidase and protein-acrolein adducts (Figure 6Ai-6Aiii) . Nevertheless, deletion of myeloperoxidase did not decrease infarct size in mice, 35 and we found that GSTP deletion increased I/R injury in bufferperfused heart, even in the absence of blood and blood-borne cells. Thus, it seems unlikely that myeloperoxidase is the major source of acrolein in the heart or that the cardioprotective effects of GSTP are related to an increase in myeloperoxidasederived products. Previous studies suggest that oxidation of polyamines by polyamine oxidase could be another source of tissue acrolein production. 34, 36 Indeed, polyamine oxidase is stimulated during cerebral ischemia, and inhibition of this enzyme or neutralization of its products diminishes neuronal cell damage during focal cerebral ischemia. 37 However, the role of polyamine oxidase in myocardial ischemia has not been well studied, and further studies are required to determine its contribution to myocardial I/R injury and to the formation of acrolein in the ischemic heart. A significant role of acrolein in I/R injury is indicated by our results showing that there is extensive accumulation of acrolein-modified proteins in the ischemic heart and that a decrease in acrolein metabolism via GSTP exacerbates I/R injury. This view is supported by the observation that disruption of GSTP decreased cardiac metabolism of acrolein and increased the sensitivity of cardiac myocytes to acrolein-induced protein crosslinking and cell death, suggesting that increased acrolein removal is an important requirement in protecting the heart from oxidative stress (Online Figure V) . However, we also found that in addition to acrolein, GSTP-null cardiac myocytes are also more sensitive to H 2 O 2 . Because GSTs have significant peroxidase activity, 38 this might mean that GSTP protects the heart from I/R injury by removing peroxides. Yet, peroxides cause cell injury by generating free radicals, which were not increased in GSTP-null hearts. Moreover, peroxides increase the formation of aldehydes such as HNE and cause GSH depletion; both of which were also not affected in GSTP-null hearts. These observations suggest that increased ischemic injury in the GSTP-null hearts is not because of greater accumulation of peroxides, but an accumulation of specific aldehydes (such as acrolein) seems to be the most likely mechanism both of increased I/R injury in GSTP-null hearts and the increase in the sensitivity of the GSTP-null myocytes to H 2 O 2 .
Our investigation into the mechanism of acrolein-induced cell death revealed that acrolein treatment caused changes in sodium current. These included a shift in the voltage dependence of inactivation to more negative potential leading to a significant increase in the window current. These changes are similar to those previously reported for oxidants, such as tertbutyl hydroperoxide, 14 and lipid peroxidation products such as HNE 18 and isoketal. 39 In cells exposed to HNE 18 and peroxide, 40 the increase in the window current was accompanied by prolongation of the action potential, increased arrhythmogenesis, and elevation in intracellular sodium. This increase in intracellular sodium has been suggested to increase [Ca 2+ ] i , presumably via Na + -Ca 2+ exchange, and could lead to Ca 2+ -induced rigor and hypercontracture.
14 Our results with acrolein suggest a similar mechanism of cell death that is further supported by the observation that treatment with SN-6, an NCX1 Na + /Ca 2+ exchange inhibitor, 17 delayed acrolein-induced myocyte hypercontracture, implicating calcium overload as a major trigger of cell death, as suggested before. 41 Both dysregulation of sodium current and calcium overload are also important features of myocardial ischemic injury, which leads to contractile filament hypercontracture, myocyte necrosis, 42 and arrhythmogenesis. Thus, taken together, our observations imply that by altering sodium current and increasing calcium overload, lipid peroxidation products, such as acrolein, could contribute at least in part to I/R-induced myocardial necrosis and sudden cardiac death (Online Figure V) . GSTP could protect against such injury by removing acrolein and related toxicants, which is consistent with our observation that GSTP-null myocytes were more sensitive to both peroxide and acrolein-induced cell death.
The lack of an increase in free radicals in GSTP-null hearts (compared with I/R WT hearts) suggests that even with the same levels of free radical generation, ischemic injury could be significantly attenuated by increasing aldehyde removal. Numerous studies show that overexpression of antioxidant enzymes, such as CuZn-SOD, 43 MnSOD, 44 catalase, 45 ecSOD, 21 and glutathione peroxidase, 46 prevents I/R injury, and mice with deficiency of MnSOD, 47 CuZn-SOD, 48 or glutathione peroxidase 49 are more sensitive to ischemic injury. Collectively, these studies provide compelling evidence that free radicals generated during I/R are an important cause of tissue injury. Our observations do not contradict this view but extend our understanding of the nature of the oxidative injury by showing that it is not necessarily the free radicals themselves but the secondary products they generate that are the proximal cause of injury. We support this view by showing that the levels of free acrolein are significantly increased in the ischemic heart ( Figure 5C ). Thus, in addition to quenching free radicals, removing aldehydes such as acrolein may be another therapeutically useful approach for preventing myocardial I/R injury. Interestingly, intravenous GSTP1 administration seems to reduce the deleterious remodeling after myocardial infarction. 50 GSTP is a highly inducible enzyme and is robustly upregulated by dietary components, such as cruciferous vegetables. 51 Therefore, the cardioprotective effects of increased vegetable consumption could be in part because of GSTP induction, and therefore, dietary or pharmacological induction of GSTP may be an important therapeutic strategy for preventing and limiting myocardial ischemic injury.
The observation that disruption of GSTP increases myocardial I/R injury in mice raises the possibility that variations in GST activity because of induction, diet, xenobiotic exposure, or genetic polymorphism could also affect ischemic injury in humans. In humans, several polymorphic forms of GSTs have been identified; however, meta-analyses of the link between GST polymorphisms and heart disease have led to discordant results. 52, 53 In white males, the GSTM1-null phenotype is common (50%), and it has been associated with increases in cardiovascular disease risk associated with air pollution by decreasing heart rate variability, 54 although it has been associated as well with a decreased risk of acute myocardial infarction. 55 Similarly, polymorphic forms of GSTT1 are also common and are associated with increased risk of cardiovascular disease in diabetics who smoke cigarettes. 56 Like other GSTs, the human GSTP1 gene is also highly polymorphic (42 known polymorphisms), and a single-nucleotide polymorphism A313G (I104V) increases the relative risk of congestive heart failure in adults who were treated for childhood leukemia with anthracyclines. 57 Protein variants of human GSTP differ in their catalytic efficiency with substrates, such as acrolein. 58 Therefore, polymorphic forms of human GSTP might vary in their ability to remove acrolein and related aldehydes from the heart and thereby significantly modify the outcomes of ischemic episodes. Thus, our studies showing that GSTP is a cardioprotective gene could form the basis of future studies to investigate the role of human GSTP1 polymorphisms in clinical outcomes of acute myocardial infarction and heart failure.
Supplemental Methods:
Mice. Glutathione S-transferase-P1/P2 WT and null mice were generated on a MF1 background strain using homologous recombination as reported. 1 µL diluted cDNA and 3 µL of mouse GST isoform specific (Online Table I ) or mGAPDH (internal control) primers (for a total of 10 µL final volume) and subjected to qRT-PCR using standard protocols on the Applied Biosystems 7900 HT Real-Time PCR system. For each RNA sample, cDNAs were run in triplicate for each primer set in the same plate along with GAPDH.
The RQ of GSTs for each RNA sample was determined by 2 −ΔΔCT , where ΔCT= (average of triplicate CT Target GST − average of triplicate CT endogenous control GAPDH ) and ΔΔCT= (average
GST Enzymatic Activity: Total GST conjugating activity toward substrates 1-chloro-2,4-dinitrobenzene (CDNB; 1 mM) and ethacrynic acid (EA; 200 µM) was determined in cardiac homogenates according to Habig et al., (1974) 2 and as previously reported.
3, 4
Ischemia/Reperfusion-Induced Cardiac Injury. Male WT and GSTP-null mice (12) (13) (14) (15) (16) weeks old) were used. Mice had free access to food and water in all treatments.
Echocardiography: Echocardiography was performed on Avertin-anesthetized male mice (12-16 weeks old; Philips Sonos 5500 Ultrasound System). In a subset of mice, a Millar pVR-1045 1 Fr catheter was inserted into LV via right carotid artery and aortic valve to record basal LV pressures.
Cardiac Abundance of Antioxidant Proteins and Activity, Glutathione and Markers of
Oxidative Stress: To determine if basal oxidative stress was increased in hearts of GSTP-null mice, expression levels of protein and activities of several well-known antioxidant enzymes, including aldose reductase (AR), thioredoxin (Trx), γ-glutamatyl cysteine ligase (GCL; rate limiting enzyme in GSH synthesis), and heme oxygenase-1 (HO-1; a Nrf-2 inducible protein),
were measured by Western blotting in GSTP-null and WT mice using commercially-available or in-house antibodies. Activities of superoxide dismutase (SOD), catalase, and glutathione peroxidase (H 2 O 2 and cumene hydroperoxide) were measured using standard techniques in heart homogenates. For measurement of cardiac levels of reduced (GSH) and oxidized (GSSG) glutathione, a recycling kit was used (Biooxytech GSH/GSSG-412, Oxis International, Inc., Foster City, CA, USA; sold by Percipio Biosciences). The hearts were powdered using liquid N 2 and a Bessman tissue pulverizer. Powders were divided into two aliquots (10 mg) that were homogenized in a water solution containing ice-cold 5% metaphosphoric acid (80 µl/mg tissue) with and without 1-methyl-2-vinyl-pyridiniumtrifluoromethane sulphonate (M2VP; 10% v/v), which binds with free GSH. The homogenates were then centrifuged at 16,000xg for 15 min at 4°C. For GSH, supernatant (4 µl) was mixed with 96 µl GSH assay buffer. For GSSG measurement, 5 µl of the supernatant (with M2VP) was mixed with 95 µl GSSG assay buffer.
For both assays, samples were mixed with 300 µl of chromagen, glutathione reductase, and allowed to incubate for 5 min (RT). The assay reaction was then started with the addition of 300 µL NADPH, and the reduction of dithiobis-2-nitrobenzoic acid (DTNB) was monitored by measuring absorbance at 412 nm for 3 min (RT). The rates of reduction of the samples were used to calculate the amount of GSH and GSSG by interpolation of linear standard curves. In addition, the basal level of lipid peroxidation was measured in WT and null heart homogenates as total carbonyl content using OxyBlot kit (Chemicon, Inc).
To analyze protein-acrolein and protein-4-hydroxy-trans-2-nonenal (HNE) adducts, Western blots were probed with in-house raised rabbit polyclonal anti-protein-acrolein or antiprotein-HNE antibodies and thiobarbituric acid reactive species (TBARS) according to previously published methods. [5] [6] [7] In brief, hearts were homogenized in lysis buffer (25 mM Tris; 0.5 mM EDTA; 0.5 mM EGTA; protease inhibitor 1:100 dilution; phosphatase inhibitor, 1:100; pH 7.5), centrifuged (14,000xg, 15 min, 4°C), pellets re-suspended in lysis buffer supplemented with 1% NP-40, incubated for 4h 8 , re-centrifuged, and supernatant used as membrane fraction.
Total protein was measured using a commercially available kit (Bradford, Bio-Rad, Hercules, CA, USA 
Electron Paramagnetic Resonance Spin Trapping Measurement of Oxygen Radicals:
After intraperitoneal induction of anesthesia (sodium pentobarbital, Abbott Laboratories, Abbott
Park, Ill), the heart was excised, and the ascending aorta was cannulated and perfused at a constant flow (2 mL/min) with Krebs-Henseleit buffer. After 15 min ischemia, the spin trap, 5,5-dimethyl-1-pyrroline-N-oxide (DMPO; 1 M; Dojindo Laboratories, Kumamoto, Japan) in buffer containing 100 µM diethylenetriaminepentaacetic acid (DPTA; Sigma Aldrich) was delivered immediately upon reperfusion via infusion (100 µL/min) through a side arm located close to the heart. During reperfusion, 20s collections of the effluent were made until 5 min of reperfusion as indicated. On sample collection, each tube was immediately frozen in lN 2 . Electron paramagnetic resonance spectra were recorded as described previously. cells. Survival data were modeled using the Weibull survival distribution.
parameters were described, these were used to find the mean lifetime using the formula: µ= Γ(1+1/γ)/λ. Cardiomyocyte viability also was measured by post-exposure incubation with MTT reagent (500 µg/ml) and measurement of solubilized MTT absorbance at 595 nm as described previously. to the experiment. Upon attaining whole cell access by brief suction pulses, the cell was held at95mV and cell capacitance and series resistance were estimated from a small depolarizing pulse (5mV) using Clampex software (Axon Instruments). Following breakthrough, series resistance for all analyzed cells was 4.8 ± 0.4 MΩ (SEM), and was compensated by 85%. To account for any slight changes in series resistance, compensation was readjusted preceding each recording.
For analysis of the steady state activation (m ∞ ) of I Na , I Na was determined by depolarizing cardiomyocytes from a -95mV holding potential to various test pulses ranging from -80 to +20 mV, in 5mV steps lasting 50 ms. The sodium conductance (g Na ) of the maximal current (I Na, peak) at each potential (V) was calculated according to equation 1:
Eq. 1: g Na = (I Na, peak ) / (V-V rev )
where V rev was the reversal potential during each recording. 
where V m is the membrane voltage at half-maximal m ∞ and s is the slope factor.
The voltage dependence of steady-state inactivation of I Na was calculated with data generated by using the classic two-pulse protocol. 15 Cardiac myocytes were depolarized to25mV for 50 ms from a holding potential of -95 mV (test pulse). The test pulse was preceded by a 500 ms conditioning pulse, which varied from -120 to -45 mV, in 5 mV increments. The ratio of the current elicited with and without the test pulse was found at each conditioning pulse potential, and was also fitted by the Boltzmann model, equation 3:
where V h is the membrane voltage at half-maximal h ∞ and k is the slope factor.
The effect of acrolein (50 µM) on V 1/2-act was determined by comparing control values measured immediately prior to addition of acrolein with that determined after 20 min acrolein exposure. To confirm that any change obtained was not the result of rundown, time-control experiments were performed in which V 1/2-act was measured before and after 20 min of vehicle (PBS) perfusion.
Cardiac Biochemistry. Hearts were weighed, and then snap frozen in lN 2 for Western blotting and biochemical analyses. Glutathione (reduced GSH) and thiobarbituric acid (TBARS) levels were determined spectrophotometrically using MDA as standard as in previously published methods. Histology and Immunohistochemistry. General histology was performed on 10% formalinfixed, paraffin-embedded tissue sections (4 µm) stained with H&E, rabbit polyclonal primary antibody against human GSTP1 (1:1,500; Novocastra) 18 , IgG-purified polyclonal rabbit antiprotein-acrolein antibody (1:1,000; IgG-purified preimmune rabbit serum served as negative control) 3 or murine anti-myeloperoxidase antibody (MPO, Ab-1; Thermo Fisher Scientific) 3 .
Secondary antibody was an anti-rabbit goat antibody used with a Vector Elite staining kit (HRPtagged) using diaminobenzadine (DAB) as chromagen (1:1000; Vector). Images of mid-heart cross sections were made using a digital Spot camera mounted on an Olympus microscope and analyzed using Metamorph (Molecular Devices) or Image J (NIH).
Calculations and Statistics:
Western blots were detected using a Typhoon 9600 and analysed band density of interest was normalized to actin or amido black band density. Values shown are means ± SE. Additional group data were compared using paired or unpaired t-test or One Way ANOVA with repeated measures and Bonferroni post-test where appropriate (SigmaStat, SPSS, Inc., Chicago, Il). Significance level in all treatments was set at P<0.05.
Chemicals and Solutions:
All chemicals were purchased from Sigma Chemical Co. promoting calcium overload via the Na + -Ca 2+ exchanger (pink) followed by cell hypercontracture and death.
Online Table I Values are means ± S.E. in nmol/mg heart wet weight. * P<0.05 between P and I; § P<0.05 between WT and matched GSTP-null by One Way ANOVA. n = number of hearts.
